Based on observational data, a 2011 report identified an increased risk for pancreatitis and pancreatic cancer in patients on incretin therapy4, which led to a Food and Drug Administration (FDA) warning on the pancreatic safety of GLP-1 agonists5. The gene discussed is GLP1R; the disease is familial pancreatic carcinoma.